Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 5/2014

01-10-2014 | Original Article

Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma

Authors: Songfeng Wei, Ming Gao, Cui Zhao, Yi Pan, Haixin Li, Jian Li, Xiaolong Li

Published in: International Journal of Clinical Oncology | Issue 5/2014

Login to get access

Abstract

Background

A decreased radioiodine uptake is associated with high recurrence rate and reduced survival in papillary thyroid carcinoma (PTC). Sodium iodide symporter (NIS) expression status in aggressive PTC variants is unknown.

Methods

NIS expression in conventional PTC and aggressive PTC variants such as tall cell variant (TCV) and diffuse sclerosing variant (DSPTC) was investigated using immunohistochemical detection.

Results

Patients having TCV and DSPTC were significantly more likely to have extrathyroidal extension and lymph nodes metastases (P < 0.05). Positive NIS staining was identified in 228 of 312 (73.1 %) patients with conventional PTC, 9 of 28 (32.1 %) patients with TCV and 12 of 30 (40.0 %) patients with DSPTC. NIS expression distinguished conventional PTC from TCV and DSPTC significantly (P < 0.01).

Conclusion

Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis.
Literature
1.
Rivera M, Ghossein RA, Schoder H et al (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48–56PubMedCrossRef
2.
Mehta RS, Negin B, Popii V et al (2008) An aggressive radio-resistant papillary thyroid cancer. Clin Adv Hematol Oncol 6:761–767PubMed
3.
Kloos RT (2008) Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93:1519–1525PubMedCrossRef
4.
Dohan O, Carrasco N (2003) Advances in Na(+)/I(−) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59–70PubMedCrossRef
5.
Castro MR, Bergert ER, Beito TG et al (1999) Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163:495–504PubMedCrossRef
6.
Falvo L, Giacomelli L, D’Andrea V et al (2006) Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 72:438–444PubMed
7.
Gonzalez–Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG et al (2011) Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature. ISRN Oncol 2011:915925PubMedPubMedCentral
8.
Chow SM, Chan JK, Law SC et al (2003) Diffuse sclerosing variant of papillary thyroid carcinoma–clinical features and outcome. Eur J Surg Oncol 29:446–449PubMedCrossRef
9.
Silver CE, Owen RP, Rodrigo JP et al (2011) Aggressive variants of papillary thyroid carcinoma. Head Neck 33:1052–1059PubMedCrossRef
10.
Hawk WA, Hazard JB (1976) The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 43:207–215PubMedCrossRef
11.
Stern Y, Medelia O, Feinmesser M et al (1996) Nuclear DNA content of the tall cell variant of papillary carcinoma of the thyroid gland. Ann Otol Rhinol Laryngol 105:713–715PubMedCrossRef
12.
Kumarasinghe MP, Kollure SK (1996) An aggressive variant of papillary carcinoma of thyroid: the tall cell type. Ceylon Med J 41:25–27PubMed
13.
Lam AK, Lo CY (2006) Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13:176–181PubMedCrossRef
14.
Mizukami Y, Nonomura A, Michigishi T et al (1990) Diffuse sclerosing variant of papillary carcinoma of the thyroid. Report of three cases. Acta Pathol Jpn 40:676–682PubMed
15.
van den Brekel MW, Hekkenberg RJ, Asa SL et al (1997) Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 107:254–259PubMedCrossRef
16.
Martins-Filho R, Ward LS, Amorim BJ et al (2010) Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: knowing when to stop. Arq Bras Endocrinol Metabol 54:807–812PubMed
17.
Albareda M, Puig-Domingo M, Wengrowicz S et al (1998) Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 8:385–391PubMedCrossRef
18.
Morari EC, Marcello MA, Guilhen AC et al (2011) Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol (Oxf) 75:247–254CrossRef
19.
Castro MR, Bergert ER, Goellner JR et al (2001) Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86:5627–5632PubMedCrossRef
20.
Ostrowski ML, Merino MJ (1996) Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964–974PubMedCrossRef
21.
Ozaki O, Ito K, Mimura T et al (1996) Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695–698PubMedCrossRef
Metadata
Title
Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma
Authors
Songfeng Wei
Ming Gao
Cui Zhao
Yi Pan
Haixin Li
Jian Li
Xiaolong Li
Publication date
01-10-2014
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0620-z

Other articles of this Issue 5/2014

International Journal of Clinical Oncology 5/2014 Go to the issue

Original Article

Five-year potency preservation after iodine-125 prostate brachytherapy

Original Article

Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation

Review Article

Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy

Original Article

Isomorphic red blood cells using automated urine flow cytometry is a reliable method in diagnosis of bladder cancer

Original Article

Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan

Original Article

Massage interventions and treatment-related side effects of breast cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits